Key result
Maternal ERV-3 stop mutation shows no association with congenital heart block.
Why the study?
Autoantibodies to ERV-3 envelope proteins have been implicated in congenital heart block, but the role of a natural ERV-3 knockout polymorphism in mothers is unclear.
Does maternal homozygosity for the ERV-3 stop polymorphism contribute to the pathogenesis of congenital heart block?
Observational (n=12)
Does maternal homozygosity for the ERV-3 stop polymorphism contribute to the pathogenesis of congenital heart block?
The ERV-3 stop polymorphism in mothers does not appear to be the primary driver of congenital heart block pathogenesis, though other polymorphisms may still be involved.
Answers are grounded in this paper and cite their sources.
Does not implicate maternal ERV-3 stop mutation in congenital heart block; leaves open other polymorphisms or autoimmune factors for further study.
Congenital heart block is a serious condition with significant mortality due in most cases to the transplacental transfer of autoantibodies from an otherwise asymptomatic mother. Although SSA/Ro and SSB/La autoantibodies have been implicated, attention has focused recently on autoantibodies to envelope proteins of endogenous retrovirus-3 (ERV-3). We have recently identified in 1% of the caucasian population a natural knock out of ERV-3 due to a premature stop mutation generating a severely truncated form of the protein [corrected]. If a pregnant female homozygous for the truncated form of the ERV-3 carries a foetus expressing the entire protein, the mother might be expected to acquire high titre immunity, while the foetus homozygous for the truncated form would not be expected to immunise its mother. In order to test whether this naturally occurring model could shed light on the pathogenesis of CHB, we determined the status of the ERV-3 stop polymorphism in 12 mothers of CHB infants [corrected]. The fact that none was homozygous for the stop mutation tends to rule out a role for the stop polymorphism of the mothers in the generation of the CHB disease, but does not exclude that other polymorphisms might be involved [corrected].
No takes yet. Share an insight, caveat, or question.
Parseval et al. (1999) conducted an observational in Congenital heart block (n=12). ERV-3 stop polymorphism was evaluated on Homozygosity for the ERV-3 stop mutation. None of the 12 mothers of infants with congenital heart block were homozygous for the ERV-3 stop mutation, suggesting this polymorphism does not play a role in generating the disease.
Synapse has enriched 10 related papers. Consider them for comparative context: